X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, CASI gains global rights to the Cleave's clinical asset, CB-5339 tosylate, an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndrome.
Lead Product(s): CB-5339
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: CASI Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 20, 2023
Details:
Through the acquisition, Eikon gains Cleave’s preclinical assets, including a large chemical library spanning multiple targets in the AAA (ATPases Associated with diverse cellular Activities) family of ATPases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eikon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 20, 2023
Details:
CB-5339 is an oral second-generation, small molecule VCP/p97 inhibitor, and is currently in Phase 1 clinical trial in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms.
Lead Product(s): CB-5339
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: CASI Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
Under the terms of the agreement, Cleave and CASI will develop CB-5339 in both hematological malignancies and solid tumors, with CASI responsible for development and commercialization in China and associated markets.
Lead Product(s): CB-5339 Tosylate
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: CASI Pharmaceuticals
Deal Size: $85.0 million Upfront Cash: $5.5 million
Deal Type: Licensing Agreement March 08, 2021
Details:
First patient has been dosed with CB-5339 in a Phase 1 clinical trial of patients with relapsed/refractory acute myeloid leukemia (AML) or relapsed/refractory intermediate or high-risk myelodysplastic syndrome (MDS).
Lead Product(s): CB-5339
Therapeutic Area: Oncology Product Name: CB-5339
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
